Send Story by Email

DEA Grants Pharmaceutical Company Monopoly on Medical CBD

10-16-2018 • Activist Post

News circulated recently that the DEA had rescheduled cannabidiol (CBD), the nonpsychoactive ingredient in cannabis, but the technicalities of the agency's decision actually show their ruling is highly restrictive.

Your First Name

Your Last Name

Your Email Address

Enter one or more email addresses below. Separate multiple addresses with a semicolon (;) or a new line. Maximum 10 email addresses at one time.

To Email Address(es)

Personal Note

Also Send Daily Headlines Newsletter

Freedoms Phoenix

Online Magazine

Join-Us

Newspaper

Phone Apps

Declare Your Independence with Ernest Hancock

REAL TIME SPOT PRICES

Live Broadcast

Declare Your Independence

MENU

Send Story by Email

DEA Grants Pharmaceutical Company Monopoly on Medical CBD

FreedomsPhoenix.com